Palo Alto Investors LP Takes Position in Disc Medicine, Inc. $IRON

Key Points

• Palo Alto Investors acquired 416,646 Disc Medicine shares worth approximately $30.5 million, giving it an 10.88% ownership stake. Institutional investors collectively own 83.70% of IRON, with BlackRock and other major funds also adding or increasing positions.
• Disc Medicine shares fell 3.1% to $80.03, despite the company reporting a quarterly loss of $1.54 per share—better than the $1.71 analyst consensus. Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $106.50.
• Company insiders have recently sold shares, including the CEO’s $2.6 million sale and the COO’s $731,124 sale; insiders have sold $11.4 million worth of stock over the past 90 days.

Palo Alto Investors LP bought a new stake in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 416,646 shares of the company's stock, valued at approximately $30,473,488. Disc Medicine makes up about 0.0% of Palo Alto Investors LP's investment portfolio, making the stock its 9th largest holding. Palo Alto Investors LP owned about 10.88% of Disc Medicine as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in IRON. BlackRock Inc. purchased a new position in shares of Disc Medicine during the 2nd quarter valued at about $180,502,000. RA Capital Management L.P. increased its stake in Disc Medicine by 25.3% during the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company's stock worth $156,925,000 after buying an additional 399,026 shares in the last quarter. Vanguard Group Inc. increased its stake in Disc Medicine by 22.1% during the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company's stock worth $140,371,000 after purchasing an additional 319,621 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Disc Medicine by 28.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company's stock worth $134,839,000 after purchasing an additional 371,576 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company's stock valued at $125,557,000 after acquiring an additional 828,248 shares during the last quarter. Institutional investors own 83.70% of the company's stock.

Disc Medicine Trading Down 3.1%

Shares of Disc Medicine stock traded down $2.52 on Friday, reaching $80.03. 665,575 shares of the company's stock were exchanged, compared to its average volume of 566,987. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50. The company has a market capitalization of $306.92 million, a P/E ratio of -12.16 and a beta of 1.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The firm's 50-day moving average is $76.79 and its two-hundred day moving average is $69.97.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.71) by $0.17. Sell-side analysts predict that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Insider Transactions at Disc Medicine

In related news, CEO John D. Quisel sold 33,000 shares of the firm's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $79.15, for a total value of $2,611,950.00. Following the completion of the sale, the chief executive officer directly owned 226,064 shares in the company, valued at approximately $17,892,965.60. This trade represents a 12.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Jonathan Yen-Wen Yu sold 8,796 shares of the company's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total value of $731,123.52. Following the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $4,515,410.88. This trade represents a 13.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 153,612 shares of company stock valued at $11,431,811. 3.76% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have commented on IRON shares. Morgan Stanley reissued an "overweight" rating and issued a $90.00 target price on shares of Disc Medicine in a research report on Monday, August 17th. Wedbush reiterated an "outperform" rating and set a $88.00 target price on shares of Disc Medicine in a research report on Wednesday, June 10th. HC Wainwright upped their price target on Disc Medicine from $118.00 to $120.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Disc Medicine in a report on Friday, July 17th. Finally, Wall Street Zen raised Disc Medicine from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $106.50.

About Disc Medicine

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source